As part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...

Eris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...

The transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...

“India is a focus market for us. We aspire to break into the top 5 in India," said M.V. Ramana, CEO – Branded Markets (India & Emerging Mar...

Eris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...

The nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...

Through acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...

The drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly...

Antique Stock Broking has initiated coverage on Essel Propack with a target price of ₹240.

Accumulate Eris Lifesciences Ltd. at a price target of Rs 704.

The India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.

The acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies i...

The public offer received bids for 1.34 crore shares against the total issue size of 1.59 crore shares.

The company has plans to raise Rs 1732-1741 crore from the equity market at a price band of Rs 600-603 per equity share.

Despite being expensive, the issue holds a compelling investment proposition.